Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

NCT06440824 is registered in ClinicalTrials.gov with Shandong University as lead sponsor.

NCT NCT06440824
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06440824 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin
Lead sponsor
Shandong University
Phase
Phase 3
Overall status
Unknown status
Start date
June 1, 2024
Completion date
November 30, 2025
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ctit-chemotherapy induced thrombocytopenia